1887

Abstract

Because we experienced gentamicin failure in Klebsiella pneumoniae bacteraemia that was susceptible to gentamicin despite amikacin resistance, as determined by VITEK 2, we evaluated the true susceptibility and mechanism of resistance. We screened 2818 K. pneumoniae isolates during a 1-year period at a university hospital and reviewed anti-microbial susceptibility reports using the VITEK 2 system. The minimum inhibitory concentration was substantiated by broth microdilution (BMD), and the presence of 16S rRNA methylase genes and aminoglycoside-modifying enzymes was also investigated. A total of 131 amikacin-resistant isolates from 19 patients were gentamicin non-resistant according to the VITEK 2 system. Among these, we were able to collect isolates from 12 patients (63.2 %), and a single isolate from each patient was tested. Eleven of the gentamicin non-resistant isolates (91.7 %) showed high-level resistance to both amikacin and gentamicin by BMD in association with the armA gene. Gentamicin is not an adequate treatment option for amikacin-resistant K. pneumoniae, even if VITEK 2 reports susceptibility.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000583
2017-09-12
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/10/1448.html?itemId=/content/journal/jmm/10.1099/jmm.0.000583&mimeType=html&fmt=ahah

References

  1. Cha MK, Kang CI, Kim SH, Cho SY, Ha YE et al. In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia. Antimicrob Agents Chemother 2015;59:5834–5837 [CrossRef][PubMed]
    [Google Scholar]
  2. Jung S, Yu JK, Shin SH, Park KG, Jekarl DW et al. False susceptibility to amikacin by VITEK 2 in Acinetobacter baumannii harboring armA. Ann Clin Lab Sci 2010;40:167–171[PubMed]
    [Google Scholar]
  3. Arslan U, Tuncer I, Findik D, Bozdogan B. VITEK 2 and PHOENIX fail to detect high-level gentamicin-resistant Enterococcus faecium isolates with aac-aph gene. Indian J Med Microbiol 2011;29:198–199 [CrossRef][PubMed]
    [Google Scholar]
  4. Arena F, Giani T, Vaggelli G, Terenzi G, Pecile P et al. Accuracy of different methods for susceptibility testing of gentamicin with KPC carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2015;81:132–134 [CrossRef][PubMed]
    [Google Scholar]
  5. CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement, CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
    [Google Scholar]
  6. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007;45:88–94 [CrossRef][PubMed]
    [Google Scholar]
  7. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 2014;58:4443–4451 [CrossRef][PubMed]
    [Google Scholar]
  8. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791–1798 [CrossRef][PubMed]
    [Google Scholar]
  9. Cho SY, Huh HJ, Baek JY, Chung NY, Ryu JG et al. Klebsiella pneumoniae co-producing NDM-5 and OXA-181 carbapenemases, South Korea. Emerg Infect Dis 2015;21:1088–1089 [CrossRef][PubMed]
    [Google Scholar]
  10. Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther 2017;15:519–526 [CrossRef][PubMed]
    [Google Scholar]
  11. El-Sayed-Ahmed MA, Amin MA, Tawakol WM, Loucif L, Bakour S et al. High prevalence of bla(NDM-1) carbapenemase-encoding gene and 16S rRNA armA methyltransferase gene among Acinetobacter baumannii clinical Isolates in Egypt. Antimicrob Agents Chemother 2015;59:3602–3605 [CrossRef][PubMed]
    [Google Scholar]
  12. Tada T, Miyoshi-Akiyama T, Dahal RK, Sah MK, Ohara H et al. NDM-1 Metallo-β-Lactamase and ArmA 16S rRNA methylase producing Providencia rettgeri clinical isolates in Nepal. BMC Infect Dis 2014;14:56 [CrossRef][PubMed]
    [Google Scholar]
  13. Shoma S, Kamruzzaman M, Ginn AN, Iredell JR, Partridge SR. Characterization of multidrug-resistant Klebsiella pneumoniae from Australia carrying blaNDM-1. Diagn Microbiol Infect Dis 2014;78:93–97 [CrossRef][PubMed]
    [Google Scholar]
  14. Frasson I, Lavezzo E, Franchin E, Toppo S, Barzon L et al. Antimicrobial treatment and containment measures for an extremely drug-resistant Klebsiella pneumoniae ST101 isolate carrying pKPN101-IT, a novel fully sequenced blaKPC-2 plasmid. J Clin Microbiol 2012;50:3768–3772 [CrossRef][PubMed]
    [Google Scholar]
  15. Mezzatesta ML, Gona F, Caio C, Adembri C, dell'utri P et al. Emergence of an extensively drug-resistant ArmA- and KPC-2-producing ST101 Klebsiella pneumoniae clone in Italy. J Antimicrob Chemother 2013;68:1932–1934 [CrossRef][PubMed]
    [Google Scholar]
  16. Winstanley T, Courvalin P. Expert systems in clinical microbiology. Clin Microbiol Rev 2011;24:515–556 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000583
Loading
/content/journal/jmm/10.1099/jmm.0.000583
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error